Cognitive & Neuro

PE-22-28

Also known as Spadin analog · TREK-1 inhibitor peptide

PreliminarySubcutaneous injectionIntranasalNot FDA-approved; no completed published human trials; remains a preclinical research compound sold as a research chemical

PE-22-28 is a synthetic seven-residue peptide derived from residues 22-28 of spadin, a fragment of the sortilin propeptide. It is studied as a selective inhibitor of the TREK-1 potassium channel, a target implicated in mood regulation, and is reported to show higher TREK-1 affinity than the parent spadin molecule. In rodent behavioral models it has produced antidepressant-like effects and enhanced hippocampal neurogenesis on a faster timescale than conventional antidepressants in those models. Human data are absent.

Studied / used for

studied in rodent models for depression and antidepressant-like effects
studied for hippocampal neurogenesis
explored for TREK-1 channel modulation

Commonly reported side effects

no published human safety data; the side-effect profile in humans is uncharacterized

Preliminary. Mostly early or animal studies. This reflects the strength of the research base, not effectiveness or a recommendation.

Not medical advice.

This is an educational reference. Peptalk does not recommend, prescribe, endorse, or rate any compound, and provides no dosing information. Do not start, stop, or change any peptide, hormone, supplement, or therapy based on this page. All clinical decisions must be made with your licensed healthcare provider.

← Back to all compounds